Back to top
more

C.R. Bard, Inc. (BCR)

(Real Time Quote from BATS)

$331.24 USD

331.24
NA

-1.95 (-0.59%)

Updated Dec 28, 2017 04:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Becton, Dickinson (BDX), Bard Receive Regulatory Nod in China

by Zacks Equity Research

Favorable tidings on the regulatory front have boosted Becton, Dickinson and Company (BDX) lately. After the closure of the deal, the company will establish a new business segment.

    NutriSystem (NTRI) Adopts Multi-Brand Strategy for 2018

    by Zacks Equity Research

    NutriSystem's (NTRI) Turbo Plans and South Beach Diet likely to witness an increase in customers.

      Becton, Dickinson (BDX) a Step Closer to Bard Acquisition

      by Zacks Equity Research

      Becton, Dickinson and Company (BDX) gets FTC's nod for the acquisition of C. R. Bard.

        Merit Medical Deserves a Place in Your Portfolio: Here's Why

        by Zacks Equity Research

        A slew of bolt-on acquisitions leverages Merit Medical (MMSI) to drive inorganic growth.

          Becton, Dickinson Banks on Bard Buyout, Medical Unit Weak

          by Zacks Equity Research

          Becton, Dickinson (BDX) is steadily progressing with the acquisition of C. R. Bard. However, sluggishness in the Medical Segment is a headwind.

            EW vs. BCR: Which Stock is Poised for Better Q3 Earnings?

            by Zacks Equity Research

            Political turmoil and the health policy related battle apart, majority of the MedTech stocks' bottom line is likely to be hurt in the third quarter on escalating costs induced by consecutive hurricanes and Mexico earthquakes.

              Can CR Bard (BCR) Spring a Surprise This Earnings Season?

              by Zacks Equity Research

              We believe that the growing adoption of the company's flagship Lutonix drug coated-balloon will result in improved performance for CR Bard (BCR) in Q3.

                Becton, Dickinson's (BCR) C.R. Bard Buyout Plans Bode Well

                by Zacks Equity Research

                Becton, Dickinson and Company's (BDX) steady move toward the pending acquisition of C.R. Bard will lend it a leading position in the healthcare domain.

                  C.R. Bard Shareholders Approve Merger With Becton, Dickinson

                  by Zacks Equity Research

                  C. R. Bard, Inc. (BCR) announced that the majority of its shareholders have approved its merger with Becton, Dickinson and Company (BDX).

                    Eric Dutram headshot

                    Zacks Podcast Highlights: Let's Make a Deal: What's a Merger Arbitrage Strategy?

                    by Eric Dutram

                    Merger activity is increasing, and investors need to be prepared. This podcast discusses the 'merger arbitrage' strategy and what you need to know about this approach.

                      Is a Surprise in Store for CR Bard (BCR) in Q2 Earnings?

                      by Zacks Equity Research

                      Growing adoption of the company's flagship Lutonix drug coated-balloon is expected to benefit C.R. Bard's (BCR) performance in the second quarter.

                        Becton, Dickinson (BDX) Poised on C.R. Bard Acquisition

                        by Zacks Equity Research

                        On Jul 7, we issued an updated research report on Franklin Lakes, NJ-based Becton, Dickinson and Company (BDX).

                          MedTech Thriving on Consolidation & Expansion: Stocks to Buy

                          by Zacks Equity Research

                          The industry has some powerful long-term tailwinds of the medical device industry like mergers & acquisitions (M&A), emerging market expansion, positive demographic trends and new product innovation.

                            What Drove Becton, Dickinson (BDX) to a New 52-Week High?

                            by Zacks Equity Research

                            Share price of Becton, Dickinson and Company (BDX) , based in Franklin Lakes, NJ, Becton, scaled a new 52-week high of $196.01 on Jun 27.

                              C.R. Bard (BCR) Up 1.6% Since Earnings Report: Can It Continue?

                              by Zacks Equity Research

                              C.R. Bard (BCR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                Becton (BDX) Announces $4.5B Follow-On Share Offerings

                                by Zacks Equity Research

                                Becton, Dickinson and Company (BDX), popularly known as BD, recently announced a follow-on offering of $4.5 billion for its shares.

                                  Stock Market News for April 24, 2017

                                  by Zacks Equity Research

                                  Benchmarks finished in the red on Friday, as investors remained concerned on the outcome of the Presidential election in France

                                    C.R. Bard (BCR) Beats Q1 Earnings & Revenues, FY17 View Up

                                    by Zacks Equity Research

                                    C.R. Bard Inc. (BCR) reported adjusted earnings of $2.87 in the first quarter of 2017, exceeding the Zacks Consensus Estimate of $2.65.

                                      Bet on These 5 GARP Stocks for Solid Returns

                                      by Zacks Equity Research

                                      The GARP strategy seeks to offer an ideal investment by utilizing the best features of both value and growth investing.

                                        C. R. Bard (BCR) Well Poised for Growth, Macro Woes Remain

                                        by Zacks Equity Research

                                        We issued an updated research report on C. R. Bard Inc. (BCR) on Mar 8, 2017.

                                          C.R. Bard (BCR) Up 8.2% Since Earnings Report: Can It Continue?

                                          by Zacks Equity Research

                                          C.R. Bard (BCR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                            The Zacks Analyst Blog Highlights: C. R. Bard, Illinois Tool Works, Sherwin-Williams, Cintas and S&P Global

                                            by Zacks Equity Research

                                            The Zacks Analyst Blog Highlights: C. R. Bard, Illinois Tool Works, Sherwin-Williams, Cintas and S&P Global

                                              C. R. Bard (BCR): Moving Average Crossover Alert

                                              by Zacks Equity Research

                                              Are you a technical investor? If so, it may be time to consider C. R. Bard, Inc. (BCR) for your portfolio.

                                                C.R. Bard (BCR) Q4 Earnings & Sales Better Than Expected

                                                by Zacks Equity Research

                                                C.R. Bard Inc. (BCR) reported adjusted earnings of $2.77 in the fourth quarter of 2016, exceeding the Zacks Consensus Estimate by 4 cents and improving from the year-ago quarterly number of $2.43.

                                                  Medical Product Stocks' Earnings on Jan 26: ABMD, BCR, ABAX

                                                  by Zacks Equity Research

                                                  Let's take a look at the major Medical products stocks slated to release their quarterly reports on Jan 26.